Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis

References

• GriffithsCEBarkerJNPathogenesis and clinical features of psoriasisLancet2007370958326327117658397
   PubMed Web of Science ®Google Scholar
• LebwohlMPsoriasisLancet200336193641197120412686053
   PubMed Web of Science ®Google Scholar
• VillanovaFDi MeglioPNestleFOBiomarkers in psoriasis and psoriatic arthritisAnn Rheum Dis201372Suppl 2ii104ii11023532439
   PubMed Web of Science ®Google Scholar
• LloydPRyanCMenterAPsoriatic arthritis: an updateArthritis2012201217629823209897
   PubMedGoogle Scholar
• SieperJRudwaleitMBaraliakosXThe Assessment of Spondylo Arthritis international Society (ASAS) handbook: a guide to assess spondyloarthritisAnn Rheum Dis200968Suppl 2ii1ii4419433414
   PubMed Web of Science ®Google Scholar
• TraceyDKlareskogLSassoEHSalfeldJGTakPPTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther2008117224427918155297
   PubMed Web of Science ®Google Scholar
• ReichKBurdenADEatonJNHawkinsNSEfficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trialsBr J Dermatol2012166117918821910698
   PubMed Web of Science ®Google Scholar
• KerenskyTAGottliebABYanivSAuSCEtanercept: efficacy and safety for approved indicationsExpert Opin Drug Saf201211112113922074366
   PubMed Web of Science ®Google Scholar
• TanJKAphaleAMalaviyaRSunYGottliebABMechanisms of action of etanercept in psoriasisJ Investig Dermatol Symp Proc20071213845
   Google Scholar
• PeppelKCrawfordDBeutlerBA tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activityJ Exp Med19911746148314891660525
   PubMed Web of Science ®Google Scholar
• ZaragozaVPerezASanchezJLOliverVMartinezLAlegreVLong-term safety and efficacy of etanercept in the treatment of psoriasisActas Dermosifiliogr201010114753 Spanish20109392
   PubMedGoogle Scholar
• AlwawiEAKruligEGordonKBLong-term efficacy of biologics in the treatment of psoriasis: what do we really know?Dermatol Ther200922543144019845720
   PubMed Web of Science ®Google Scholar
• LeonardiCLPowersJLMathesonRTEtanercept Psoriasis Study GroupEtanercept as monotherapy in patients with psoriasisN Engl J Med2003349212014202214627786
   PubMed Web of Science ®Google Scholar
• KruegerGGElewskiBPappKWangAZitnikRJahreisAPatients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trialJ Am Acad Dermatol2006543 Suppl 2S112S11916488321
   PubMed Web of Science ®Google Scholar
• TyringSGordonKBPoulinYLong-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasisArch Dermatol2007143671972617576937
   PubMed Web of Science ®Google Scholar
• TyringSGottliebAPappKEtanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialLancet20063679504293516399150
   PubMed Web of Science ®Google Scholar
• Enbrel (Etanercept) [package insert]Thousand Oaks, CAImmunex Corporation2013
   Google Scholar
• PappKATyringSLahfaMEtanercept Psoriasis Study GroupA global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBr J Dermatol200515261304131215948997
   PubMed Web of Science ®Google Scholar
• LeonardiCStroberBGottliebABLong-term safety and efficacy of etanercept in patients with psoriasis: an open-label studyJ Drugs Dermatol20109892893720684143
   PubMed Web of Science ®Google Scholar
• PappKAPoulinYBissonnetteRAssessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult populationJ Am Acad Dermatol2012662e33e4520850895
   PubMedGoogle Scholar
• ElewskiBLeonardiCGottliebABComparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasisBr J Dermatol2007156113814217199580
   PubMed Web of Science ®Google Scholar
• WuJJPoonKYBebchukJDAssociation between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasisJ Drugs Dermatol201312889990323986163
   PubMed Web of Science ®Google Scholar
• CostaLCasoFAttenoMImpact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patientsClin Rheumatol Epub8202013
   Web of Science ®Google Scholar
• MeasePJGoffeBSMetzJVanderStoepAFinckBBurgeDJEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet2000356922738539010972371
   PubMed Web of Science ®Google Scholar
• MeasePPsoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanerceptClin Exp Rheumatol2002206 Suppl 28S116S12112463460
   PubMed Web of Science ®Google Scholar
• MeasePJKivitzAJBurchFXEtanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progressionArthritis Rheum20045072264227215248226
   PubMed Web of Science ®Google Scholar
• MeasePJKivitzAJBurchFXContinued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanerceptJ Rheumatol200633471272116463435
   PubMed Web of Science ®Google Scholar
• KristensenLEGulfeASaxneTGeborekPEfficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group registerAnn Rheum Dis200867336436917644547
   PubMed Web of Science ®Google Scholar
• DalyMAlikhanAArmstrongAWCombination systemic therapies in psoriatic arthritisJ Dermatol Treat2011225276284
   Web of Science ®Google Scholar
• SpadaroACeccarelliFScrivoRValesiniGLife-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritisAnn Rheum Dis200867111650165118854519
   PubMed Web of Science ®Google Scholar
• HeibergMSKoldingsnesWMikkelsenKThe comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter studyArthritiis Rheum2008592234240
   PubMed Web of Science ®Google Scholar
• DuclosMGossecLRuyssen-WitrandARetention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patientsJ Rheumatol200633122433243817014004
   PubMed Web of Science ®Google Scholar
• ChimentiMSPerriconeCGraceffaDComplement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatmentClin Exp Rheumatol2012301233022260811
   PubMed Web of Science ®Google Scholar
• GlintborgBOstergaardMDreyerLTreatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registryArthritis Rheum201163238239021279995
   PubMed Web of Science ®Google Scholar
• PariserDMLeonardiCLGordonKIntegrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisJ Am Acad Dermatol201267224525622015149
   PubMed Web of Science ®Google Scholar
• KimballABPariserDYamauchiPSOBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasisJ Am Acad Dermatol201368575676423357569
   PubMed Web of Science ®Google Scholar
• MooreAGordonKBKangSA randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisJ Am Acad Dermatol200756459860317113190
   PubMed Web of Science ®Google Scholar
• GordonKBGottliebABLeonardiCLClinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapyJ Dermatol Treat2006171917
   PubMed Web of Science ®Google Scholar
• OrtonneJPTaiebAOrmerodADPatients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanerceptBr J Dermatol200916151190119519566665
   PubMed Web of Science ®Google Scholar
• GottliebABMathesonRTLoweNA randomized trial of etanercept as monotherapy for psoriasisArch Dermatol20031391216271632 discussion 163214676082
   PubMed Web of Science ®Google Scholar
• ChenLASuLHChangYJHsuYLTsaiTHNew-onset psoriasis associated with etanercept therapyJ Dermatol Treat2010374378380
   Web of Science ®Google Scholar
• HarrisonMJDixonWGWatsonKDBritish Society for Rheumatology Biologics Register Control Centre ConsortiumBSRBRRates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics RegisterAnn Rheum Dis200968220921518385277
   PubMed Web of Science ®Google Scholar
• SaadAAAshcroftDMWatsonKDSymmonsDPNoycePRHyrichKLBSRBREfficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterRheumatology201049469770520056769
   PubMed Web of Science ®Google Scholar
• Perez-ZafrillaBAngel DescalzoMCarmona L; y Grupo de EstudioB BIOBADASERAdverse Reactions Related to the Administration of TNF Inhibitors. Analysis of a Registry of Biologic TherapyReumatol Clin2008439095 Spanish21794507
   PubMedGoogle Scholar
• CarmonaLAbasoloLDescalzoMABIOBADASER Study GroupEMECAR Study GroupCancer in patients with rheumatic diseases exposed to TNF antagonistsSemin Arthritis Rheum2011411718021093020
   PubMed Web of Science ®Google Scholar
• KircikLBagelJKormanNUNITE Study GroupUtilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomesJ Drugs Dermatol20087324525318380206
   PubMed Web of Science ®Google Scholar
• GambichlerTTiggesCScolaNEtanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeksBr J Dermatol201116461383138621466532
   PubMed Web of Science ®Google Scholar
• WolfPHoferALegatFJTreatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanerceptBr J Dermatol2009160118618919067710
   PubMed Web of Science ®Google Scholar
• De SimoneCD’AgostinoMCapizziRCapponiAVenierACaldarolaGCombined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasisEur J Dermatol201121456857221697032
   PubMed Web of Science ®Google Scholar
• InzingerMHeschlBWegerWEfficacy of psoralen plus ultraviolet A therapy vs biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registryBr J Dermatol2011165364064521564068
   PubMed Web of Science ®Google Scholar
• SternRSLiebmanEJVakevaLOral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up StudyJ Natl Cancer Inst19989017127812849731734
   PubMedGoogle Scholar
• SternRSNicholsKTVakevaLHMalignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up StudyN Engl J Med199733615104110459091799
   PubMed Web of Science ®Google Scholar
• Di LerniaVAlbertiniGIs antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe?Br J Dermatol201016251147114820128790
   PubMed Web of Science ®Google Scholar
• GottliebABLangleyRGStroberBEA randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisBr J Dermatol2012167364965722533447
   PubMed Web of Science ®Google Scholar
• FagerliKMLieEvan der HeijdeDThe role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD studyAnn Rheum Dis201473113213723291385
   PubMed Web of Science ®Google Scholar
• EderLThavaneswaranAChandranVGladmanDDTumour necrosis factor alpha blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritisAnn Rheum Dis201372457858222589379
   PubMed Web of Science ®Google Scholar
• LeeEJShinMKKimNIA clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasisAnn Dermatol201022213814220548902
   PubMed Web of Science ®Google Scholar
• D’AngeloSCutroMSLubranoECombination therapy with ciclosporin and etanercept in patients with psoriatic arthritisAnn Rheum Dis201069593493519666936
   PubMed Web of Science ®Google Scholar
• AtzeniFBoccassiniLAntivalleMSalaffiFSarzi-PuttiniPEtanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot studyAnn Rheum Dis201170471271420810394
   PubMed Web of Science ®Google Scholar
• GisondiPDel GiglioMCotenaCGirolomoniGCombining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trialBr J Dermatol200815861345134918410408
   PubMed Web of Science ®Google Scholar
• Galvan-BanqueriMMarin GilRSantos RamosBBautista PalomaFJBiological treatments for moderate-to-severe psoriasis: indirect comparisonJ Clin Pharm Ther201338212113023442134
   PubMed Web of Science ®Google Scholar
• GriffithsCEStroberBEvan de KerkhofPACCEPT Study GroupComparison of ustekinumab and etanercept for moderate-to-severe psoriasisN Engl J Med2010362211812820071701
   PubMed Web of Science ®Google Scholar
• GottliebABLeonardiCKerdelFMehlisSOldsMWilliamsDAEfficacy and safety of briakinumab vs etanercept and placebo in patients with moderate to severe chronic plaque psoriasisBr J Dermatol2011165365266021574983
   PubMed Web of Science ®Google Scholar
• Fenix-CaballeroSAlegre-del ReyEJCastano-LaraRPuigventos-LatorreFBorrero-RubioJMLopez-VallejoJFDirect and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritisJ Clin Pharm Ther201338428629323590560
   PubMed Web of Science ®Google Scholar
• EspositoMGisondiPCassanoNSurvival rate of anti-TNF alpha treatments for psoriasis in routine dermatological practice: a multicenter observational studyBr J Dermatol2013169366667223647206
   PubMed Web of Science ®Google Scholar
• GniadeckiRKragballeKDamTNSkovLComparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgarisBr J Dermatol201116451091109621219290
   PubMed Web of Science ®Google Scholar
• LangleyRSecukinumab compared with placebo and etanercept: The first 52-week head-to-head comparison of two biologics in a randomized, double-blind phase 3 study in subjects with moderate-to-severe psoriasis (FIXTURE)Oral presentation at: 22nd Congress of the European Association of Dermatology and Venereology (EADV)October 3; 2013Istanbul, Turkey
   Google Scholar
• FleischmannRBaumgartnerSWWeismanMHLiuTWhiteBPelosoPLong term safety of etanercept in elderly subjects with rheumatic diseasesAnn Rheum Dis200665337938416150792
   PubMed Web of Science ®Google Scholar
• MilitelloGXiaAStevensSRVan VoorheesASEtanercept for the treatment of psoriasis in the elderlyJ Am Acad Dermatol200655351751916908365
   PubMed Web of Science ®Google Scholar
• EspositoMGiuntaAMazzottaAEfficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term studyDermatology2012225431231923295383
   PubMed Web of Science ®Google Scholar
• PallerASSiegfriedECLangleyRGEtanercept Pediatric Psoriasis Study GroupEtanercept treatment for children and adolescents with plaque psoriasisN Engl J Med2008358324125118199863
   PubMed Web of Science ®Google Scholar
• PallerASSiegfriedECEichenfieldLFLong-term etanercept in pediatric patients with plaque psoriasisJ Am Acad Dermatol201063576276820605256
   PubMed Web of Science ®Google Scholar
• MurashimaAWatanabeNOzawaNSaitoHYamaguchiKEtanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serumAnn Rheum Dis200968111793179419822717
   PubMed Web of Science ®Google Scholar
• Cohen-BarakENachumZRozenmanDZivMPregnancy outcomes in women with moderate-to-severe psoriasisJ Eur Acad Dermatol Venereol20112591041104721108670
   PubMed Web of Science ®Google Scholar